May 30 2023 30 mins 1
Educational Objectives
- Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer
- Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer
Faculty:
Allison R. Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Breast Oncology Clinical Pharmacy Specialist
Acute Care Pharmacy Services
UK HealthCare- Markey Cancer
Lexington, Kentucky
Director, PGY2 Oncology Residency Program
UK HealthCare
Lexington, Kentucky
Allison R. Butts, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: AstraZeneca; BeyondSpring (one-time advisory boards)
Moderator:
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Laura R. Bobolts, PharmD, BCOP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-239-H01-P. The activity is available for CE credit through May 31, 2024.
This activity is supported by independent medical educational grants from AstraZeneca; Merck & Co., Inc.; Puma Biotechnology Inc., and Lilly.
